Understanding interactions like EGF‐EGFR's influence on PD‐L1 is especially relevant given the ongoing clinical trials assessing the use of afatinib (EGFR‐TKI) in advanced BC (NCT02122172). The gene discussed is EGFR; the disease is breast cancer.